uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

uniQure (NASDAQ: QURE) received final FDA minutes from a Jan 30, 2026 Type A meeting about AMT-130 for Huntington’s disease.

Rhea-AI Summary

uniQure (NASDAQ: QURE) received final FDA minutes from a Jan 30, 2026 Type A meeting about AMT-130 for Huntington’s disease. The FDA said Phase I/II data versus an external control are not sufficient to support a marketing application and strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study.

uniQure plans further engagement and intends to request a Type B meeting in Q2 2026 to discuss Phase III design options.

Positive

• FDA provided clear, specific trial-design guidance for AMT-130
• uniQure plans a Type B meeting in Q2 2026 to discuss Phase III

Negative

• FDA concluded Phase I/II data versus external control are insufficient for approval
• Regulator strongly recommended a randomized, double-blind, sham-controlled Phase III trial

Argus Mar 2 session

-32.82% close to close Open Argus

Details

News Market Reaction – QURE

On Mar 2, the day this news came out, QURE closed 32.82% below the previous close.

Data tracked by StockTitan Argus for the Mar 2 session.

Market Context

On Mar 2, the day this news came out, the stock closed 32.8% below the previous close. A negative re...

Analysis

On Mar 2, the day this news came out, the stock closed 32.8% below the previous close. A negative reaction despite ongoing dialogue fits QURE’s history of sharp moves around AMT-130 regulatory updates, including the -10.75% drop on Dec 4, 2025 after earlier FDA feedback. The FDA’s view that Phase I/II data are insufficient for a marketing application, and its push for a randomized, sham-controlled study, adds development and timing risk. Past sensitivity to regulatory news suggests that setbacks in this program have previously translated into meaningful share-price pressure.

Key Figures

Type A meeting date: January 30, 2026 Phase I/II: Phase I/II Phase III planning: Phase III +1 more

Type A meeting date

January 30, 2026

FDA Type A meeting on AMT-130 data package

Phase I/II

Phase I/II

Current AMT-130 data package level discussed with FDA

Phase III planning

Phase III

Company intends to discuss Phase III development considerations

Type B meeting timing

Q2 2026

Planned Type B meeting request to discuss AMT-130 Phase III design

Historical Context

5 past events · Latest: Feb 23

5 events

1. Feb 23

   Earnings date announcement

   24h Move

   +4.4%

   Set timing for Q4 and full-year 2025 results and conference call.

2. Feb 06

   Clinical data update

   24h Move

   +4.6%

   Reported sustained, dose-dependent α-Gal A increases in 11 Fabry patients.

3. Jan 09

   Regulatory meeting news

   24h Move

   +9.4%

   Announced Type A FDA meeting on AMT-130 BLA package and accelerated approval path.

4. Dec 07

   Durability publication

   24h Move

   +2.1%

   Published 5-year HEMGENIX durability and safety data in NEJM with strong outcomes.

5. Dec 04

   Regulatory setback

   24h Move

   -10.8%

   FDA said AMT-130 Phase I/II data unlikely to provide primary BLA evidence.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

type a meeting, type b meeting, phase i/ii, phase iii, +3 more

7 terms

type a meeting regulatory

"regarding a Type A meeting held on January 30, 2026 to discuss AMT-130"

A Type A meeting is an urgent, short-notice session requested between a company and a regulatory agency (for example, the FDA in the U.S.) to resolve critical issues that block a development program, such as a clinical hold or safety concern. Investors care because the outcome can immediately affect whether a clinical trial or approval process resumes, changing timelines, costs and the company’s near-term value — like calling an emergency mechanic when a car won’t start so a trip can continue.

type b meeting regulatory

"plans to request a Type B meeting in the second quarter of 2026"

A Type B meeting is a formal, scheduled discussion between a drug or medical-device developer and a health regulator to resolve key mid‑ or late‑stage development issues such as clinical trial plans, interpretation of results, or steps needed for approval. Like a mid‑project review with an inspector, the meeting’s outcome can meaningfully change the timeline, cost and risk for a candidate: a clear, positive outcome lowers uncertainty for investors, while requests for more data or changes can signal delays and extra expense.

phase i/ii medical

"data from the Phase I/II studies, compared to an external control"

"Phase I/II" describes early stages of testing a new medicine or treatment, where researchers first evaluate its safety and then begin to see if it works. For investors, these phases are important because they indicate whether a product is progressing toward potential approval and commercialization, which can impact future value and success prospects. These stages help gauge how close a new treatment is to reaching the market.

phase iii medical

"regarding Phase III development considerations and plans to request"

A Phase III trial is the late-stage clinical study that tests whether a medical treatment works and is safe in a large group of patients, often comparing it to standard care. Think of it as a final dress rehearsal or full-scale road test before regulators decide on approval; positive or negative results strongly influence a drug maker’s chance to sell the treatment, future revenue, and investment risk.

double-blind medical

"recommended uniQure conduct a prospective, randomized, double-blind, sham"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

sham surgery-controlled medical

"double-blind, sham surgery-controlled study"

A sham surgery-controlled trial is a medical study where the control group undergoes a mock procedure that mimics the real surgery without delivering the therapeutic step, like a placebo pill but for an operation. Investors care because results from these trials provide the clearest evidence whether a surgical treatment truly works beyond patient expectations; strong or weak findings directly affect regulatory approval, adoption by doctors, liability risk and the commercial prospects of related products or services.

gene therapy medical

"a leading gene therapy company advancing transformative therapies"

Gene therapy is a medical technique that involves altering or replacing faulty genes in a person's cells to treat or prevent disease. It is considered a promising area of innovation because it has the potential to provide long-term or even permanent solutions to genetic conditions. For investors, advancements in gene therapy can signal opportunities in biotech companies and emerging treatments with significant growth potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass. and AMSTERDAM, March 02, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the company received final meeting minutes from the U.S. Food and Drug Administration (FDA) regarding a Type A meeting held on January 30, 2026 to discuss AMT-130, an investigational gene therapy for Huntington’s disease (HD).  

The FDA stated that it cannot agree that data from the Phase I/II studies, compared to an external control, are sufficient to provide the primary evidence of effectiveness required to support a marketing application for AMT-130. The FDA strongly recommended uniQure conduct a prospective, randomized, double-blind, sham surgery-controlled study. uniQure intends to continue engaging with the FDA regarding Phase III development considerations and plans to request a Type B meeting in the second quarter of 2026 to further discuss potential study design approaches.

“While we did not reach alignment on a submission pathway based on the Phase I/II data, we believe the totality and durability of our data warrant continued substantive dialogue regarding how the FDA’s stated commitment to regulatory flexibility may be appropriately applied in this setting,” said Matt Kapusta, chief executive officer at uniQure. “We remain committed to engaging with the FDA to determine a clear, scientifically grounded, and efficient path forward for AMT-130. We are deeply grateful for the resilience and support of the Huntington’s disease community and remain committed to standing with patients and their families as we advance this potentially transformative therapy for a community in need.”

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases. www.uniQure.com

uniQure Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," “establish,” "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," “seek,” "should," "will," "would" and similar expressions and the negatives of those terms. Forward-looking statements are based on management's beliefs and assumptions and on information available to management as of the date of this press release. Examples of these forward-looking statements include, but are not limited to, statements concerning: plans to continue engaging with the FDA regarding Phase III development considerations for AMT-130; plans to request a Type B meeting with the FDA to take place in the second quarter of 2026; and the potential benefit of AMT-130. The Company’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons. These risks and uncertainties include, among others: risks related to the Company’s Phase I/ll clinical trials of AMT-130, including the risk that such trials will be unable to demonstrate data sufficient to support further clinical development or regulatory approval; the risk that more patient data become available that results in a different interpretation then the one derived from the topline data; risks related to the Company’s interactions with regulatory authorities, which may affect the initiation, timing and progress of clinical trials and pathways to regulatory approval; the risk that we will be unable to align with the FDA or other regulatory authorities on an approval pathway for our gene therapy candidates, including AMT-130; whether the measurements that the Company is evaluating are viewed as robust and sensitive measurements of disease progression; whether RMAT designation, Breakthrough Therapy designation, or any accelerated pathway, if granted, will lead to regulatory approval; the Company’s ability to conduct and fund a Phase III or confirmatory study for AMT-130; the Company’s ability to continue to build and maintain the infrastructure and personnel needed to achieve its goals; the Company’s effectiveness in managing current and future clinical trials and regulatory processes; the Company’s ability to demonstrate the therapeutic benefits of its gene therapy candidates in clinical trials; the continued development and acceptance of gene therapies; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s ability to fund its operations and to raise additional capital as needed and on acceptable terms. These risks and uncertainties are more fully described under the heading "Risk Factors" in the Company’s periodic filings with the U.S. Securities & Exchange Commission (SEC), including its Annual Reports on Form 10-K , its Quarterly Reports on Form 10-Q and in other filings that the Company makes with the SEC from time to time. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements and, except as required by law, the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts:

FOR INVESTORS:        Chiara Russo               Direct: 781-491-4371     Mobile: 617-306-9137    c.russo@uniQure.com

FOR MEDIA: Tom Malone Direct: 339-970-7558 Mobile:339-223-8541     t.malone@uniQure.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the FDA tell uniQure about AMT-130 on January 30, 2026 (QURE)?

The FDA said Phase I/II data compared to an external control are insufficient for approval. According to uniQure, the FDA strongly recommended a prospective, randomized, double-blind, sham surgery-controlled Phase III study as the preferred pathway.

Will uniQure (QURE) advance AMT-130 to a Phase III randomized sham-controlled study?

uniQure has not committed to a specific Phase III start date but intends further discussions. According to uniQure, it will continue engaging with the FDA and request a Type B meeting in Q2 2026 to discuss potential study design approaches.

What does the FDA recommendation mean for AMT-130 approval timeline for uniQure (QURE)?

The FDA recommendation implies additional randomized Phase III work is likely required, which may extend timelines. According to uniQure, the agency’s guidance suggests a new prospective, sham-controlled trial would be needed to provide primary evidence of effectiveness.

How will uniQure (QURE) engage the FDA after the Type A meeting on AMT-130?

uniQure plans to keep engaging and will request a Type B meeting in Q2 2026. According to uniQure, discussions will focus on Phase III development considerations and potential study design approaches.

Did the FDA agree that uniQure’s Phase I/II AMT-130 data are sufficient for a marketing application (QURE)?

No, the FDA did not agree the Phase I/II data versus an external control are sufficient for approval. According to uniQure, the agency emphasized the need for a prospective, randomized, double-blind, sham surgery-controlled study.

What is uniQure’s public response after the FDA feedback on AMT-130 (QURE)?

uniQure said it values the data’s totality and durability and will continue discussions with the FDA. According to uniQure, the company remains committed to finding a scientifically grounded and efficient path forward for AMT-130.